| Literature DB >> 34664389 |
Marek Ostaszewski1, Anna Niarakis2,3, Alexander Mazein1, Inna Kuperstein4,5,6, Robert Phair7, Aurelio Orta-Resendiz8,9, Vidisha Singh2, Sara Sadat Aghamiri10, Marcio Luis Acencio1, Enrico Glaab1, Andreas Ruepp11, Gisela Fobo11, Corinna Montrone11, Barbara Brauner11, Goar Frishman11, Luis Cristóbal Monraz Gómez4,5,6, Julia Somers12, Matti Hoch13, Shailendra Kumar Gupta13, Julia Scheel13, Hanna Borlinghaus14, Tobias Czauderna15, Falk Schreiber14,15, Arnau Montagud16, Miguel Ponce de Leon16, Akira Funahashi17, Yusuke Hiki17, Noriko Hiroi18, Takahiro G Yamada17, Andreas Dräger19,20,21, Alina Renz19,20, Muhammad Naveez13,22, Zsolt Bocskei23, Francesco Messina24,25, Daniela Börnigen26, Liam Fergusson27, Marta Conti28, Marius Rameil28, Vanessa Nakonecnij28, Jakob Vanhoefer28, Leonard Schmiester28,29, Muying Wang30, Emily E Ackerman30, Jason E Shoemaker30,31, Jeremy Zucker32, Kristie Oxford32, Jeremy Teuton32, Ebru Kocakaya33, Gökçe Yağmur Summak33, Kristina Hanspers34, Martina Kutmon35,36, Susan Coort35, Lars Eijssen35,37, Friederike Ehrhart35,37, Devasahayam Arokia Balaya Rex38, Denise Slenter35, Marvin Martens35, Nhung Pham35, Robin Haw39, Bijay Jassal39, Lisa Matthews40, Marija Orlic-Milacic39, Andrea Senff Ribeiro39,41, Karen Rothfels39, Veronica Shamovsky40, Ralf Stephan39, Cristoffer Sevilla42, Thawfeek Varusai42, Jean-Marie Ravel43,44, Rupsha Fraser45, Vera Ortseifen46, Silvia Marchesi47, Piotr Gawron1,48, Ewa Smula1, Laurent Heirendt1, Venkata Satagopam1, Guanming Wu49, Anders Riutta34, Martin Golebiewski50, Stuart Owen51, Carole Goble51, Xiaoming Hu50, Rupert W Overall52,53,54, Dieter Maier55, Angela Bauch55, Benjamin M Gyori56, John A Bachman56, Carlos Vega1, Valentin Grouès1, Miguel Vazquez16, Pablo Porras42, Luana Licata57, Marta Iannuccelli57, Francesca Sacco57, Anastasia Nesterova58, Anton Yuryev58, Anita de Waard59, Denes Turei60, Augustin Luna61,62, Ozgun Babur63, Sylvain Soliman3, Alberto Valdeolivas60, Marina Esteban-Medina64,65, Maria Peña-Chilet64,65,66, Kinza Rian64,65, Tomáš Helikar67, Bhanwar Lal Puniya67, Dezso Modos68,69, Agatha Treveil68,69, Marton Olbei68,69, Bertrand De Meulder70, Stephane Ballereau71, Aurélien Dugourd60,72, Aurélien Naldi3, Vincent Noël4,5,6, Laurence Calzone4,5,6, Chris Sander61,62, Emek Demir12, Tamas Korcsmaros68,69, Tom C Freeman73, Franck Augé23, Jacques S Beckmann74, Jan Hasenauer75,76, Olaf Wolkenhauer13, Egon L Wilighagen35, Alexander R Pico34, Chris T Evelo35,36, Marc E Gillespie39,77, Lincoln D Stein39,78, Henning Hermjakob42, Peter D'Eustachio40, Julio Saez-Rodriguez60, Joaquin Dopazo64,65,66,79, Alfonso Valencia16,80, Hiroaki Kitano81,82, Emmanuel Barillot4,5,6, Charles Auffray71, Rudi Balling1, Reinhard Schneider1.
Abstract
We need to effectively combine the knowledge from surging literature with complex datasets to propose mechanistic models of SARS-CoV-2 infection, improving data interpretation and predicting key targets of intervention. Here, we describe a large-scale community effort to build an open access, interoperable and computable repository of COVID-19 molecular mechanisms. The COVID-19 Disease Map (C19DMap) is a graphical, interactive representation of disease-relevant molecular mechanisms linking many knowledge sources. Notably, it is a computational resource for graph-based analyses and disease modelling. To this end, we established a framework of tools, platforms and guidelines necessary for a multifaceted community of biocurators, domain experts, bioinformaticians and computational biologists. The diagrams of the C19DMap, curated from the literature, are integrated with relevant interaction and text mining databases. We demonstrate the application of network analysis and modelling approaches by concrete examples to highlight new testable hypotheses. This framework helps to find signatures of SARS-CoV-2 predisposition, treatment response or prioritisation of drug candidates. Such an approach may help deal with new waves of COVID-19 or similar pandemics in the long-term perspective.Entities:
Keywords: computable knowledge repository; large-scale biocuration; omics data analysis; open access community effort; systems biomedicine
Mesh:
Substances:
Year: 2021 PMID: 34664389 PMCID: PMC8524328 DOI: 10.15252/msb.202110387
Source DB: PubMed Journal: Mol Syst Biol ISSN: 1744-4292 Impact factor: 11.429
Figure 1Ecosystem of the COVID‐19 Disease Map Community
The main groups of the C19DMap Community are biocurators, domain experts, and analysts and modellers; communicating to refine, interpret, and apply C19DMap diagrams. These diagrams are created and maintained by biocurators, following pathway database workflows or stand‐alone diagram editors, and reviewed by domain experts. The content is shared via pathway databases or a GitLab repository; all can be enriched by integrated resources of text mining and interaction databases. The C19DMap diagrams are available in several layout‐aware systems biology formats and integrated with external repositories, allowing a range of computational analyses, including network analysis and Boolean, kinetic or multiscale simulations.
COVID‐19 Disease Map contents.
| Source | |||
|---|---|---|---|
| Individual diagrams | Reactome | WikiPathways | |
| Diagram contents |
21 diagrams 1,334 interactions 4,272 molecular entities 397 publications |
2 diagrams 101 interactions 489 molecular entities 227 publications |
19 diagrams 401 interactions 738 molecular entities 61 publications |
| Access |
GitLab
|
SARS‐CoV‐1 and SARS‐CoV‐2 infections collection
|
COVID pathway collection
|
| Exploration |
The MINERVA Platform (Gawron
Guide: |
Native web interface Guide: |
Native web interface Guide: |
| Biocuration guidelines | Community | Platform‐specific | Platform‐specific |
| Diagram Editors | CellDesigner (Matsuoka | Reactome pathway editor |
PathVisio (Kutmon |
| Formats |
CellDesigner SBML SBGNML (Bergmann | Internal, SBML and SBGNML compliant | GPML (Kutmon |
The table summarises biocuration resources and content of the C19DMap across three main parts of the repository. All diagrams are listed in Table EV1, and available online at: https://covid.pages.uni.lu/map_contents.
https://fairdomhub.org/documents/661
https://reactome.org/community/training
https://www.wikipathways.org/index.php/Help:Editing_Pathways
https://newteditor.org
https://github.com/sbgn/ySBGN
Resources supporting biocuration of the COVID‐19 Disease Map.
| Resource | Type | Manually curated | Directed | Layout | COVID‐19 specific |
|---|---|---|---|---|---|
| IMEx Consortium (Orchard | Interaction database | Yes | No | No | Yes |
| SIGNOR 2.0 (Licata | Yes | Yes | Yes | Yes | |
| OmniPath (Türei | No | Yes | No | No | |
| Elsevier Pathway Collection | Pathway | Yes | Yes | Yes | Yes |
| INDRA (Gyori | Text mining | Yes | Yes | No | Yes |
| BioKB | No | Yes | No | Yes | |
| AILANI COVID‐19 | No | Yes | No | Yes | |
| OpenNLP+GNormPlus | No | Yes | No | Yes |
They include (i) collections of COVID‐19 interactions and pathways, (ii) interaction databases and (iii) text mining corpora.
https://www.ebi.ac.uk/intact/resources/datasets#coronavirus
https://signor.uniroma2.it/covid/
https://pathwaystudio.com
http://dx.doi.org/10.17632/d55xn2c8mw.1
https://emmaa.indra.bio/dashboard/covid19
https://biokb.lcsb.uni.lu
https://ailani.ai
https://gitlab.lcsb.uni.lu/covid/models/‐/tree/master/Resources/Text%20mining
Figure 2The structure and content of the COVID‐19 Disease Map
An overview of the areas of focus of the C19DMap biocuration. Go to covid19map.elixir‐luxembourg.org for an interactive version. Full list of diagrams and browsing instructions are available online at covid.pages.uni.lu/map_contents.
Figure 3Overview of the C19DMap in the context of COVID‐19 progression
The figure summarises the main sections and content of the C19DMap by illustrating the progressive but overlapping mechanisms at different levels and study features of the disease intended as quick references for the map.
Cellular level (light yellow), the immune response (blue) and other systemic responses (red) of the host following SARS‐CoV‐2 infection.
The progression of pathophysiology from tissue damage to organ damage and multiple organ dysfunction in severe cases.
Clinical manifestations, depending on the severity of the infection from asymptomatic to critical COVID‐19.
Potential intervention strategies that may be suggested based on the analysis of the C19DMap before, during and after infection, depending on the type and target of the intervention.
Clinical outcomes of SARS‐CoV‐2 infection. ARDS, acute respiratory distress syndrome. RAAS, renin–angiotensin–aldosterone system. SIRS, systemic inflammatory response syndrome. For the literature on clinical manifestations, see Lauer et al, 2020; He et al, 2020; Huang et al, 2020; Bajema et al, 2020; preprint: Chen et al, 2020b; Wang et al, 2020a; Tong et al, 2020.
Figure 4Exploration of the existing and candidate crosstalk between the diagrams of the COVID‐19 Disease Map
The network structure of the diagrams and their interactions based on existing crosstalk (shared elements), candidate crosstalk, and candidate regulators. Colour code: green—pathways or pathway groups; blue—proteins with one or two neighbours; yellow—proteins with three or four neighbours; and red—proteins with five or more neighbours. Candidate molecular interactions are shown as directed edges. Candidate regulator elements are marked with a solid black border. See Materials and Methods for details.
Existing crosstalk between individual diagrams of IFN‐I and RELA‐related mechanisms.
Candidate crosstalk between pathway groups.
Candidate regulators of existing diagrams from text mining and interaction databases.
Figure EV1Exploration of the existing crosstalk between the diagrams of the COVID‐19 Disease Map
The network structure of the diagrams and their interactions based on existing crosstalk (shared elements). Colour code: green—pathways; blue—proteins with one or two neighbours; yellow—proteins with three or four neighbours; and red—proteins with five or more neighbours. See Materials and Methods for details.
Figure EV2Exploration of the existing crosstalk between the groups of diagrams of the COVID‐19 Disease Map
The network structure of the diagrams and their interactions based on existing crosstalk (shared elements). Colour code: green—pathway groups; blue—proteins with one or two neighbours, yellow—proteins with three or four neighbours; and red—proteins with five or more neighbours. See Materials and Methods for details.
Figure EV3Exploration of new crosstalk between the diagrams of the COVID‐19 Disease Map
The network structure of the diagrams and their interactions based on new crosstalk. Colour code: green—pathways; blue—proteins with one or two neighbours; yellow—proteins with three or four neighbours; and red—proteins with five or more neighbours. New molecular interactions are shown as directed edges. See Materials and Methods for details.
Examples of computational workflows using the COVID‐19 Disease Map
| Workflow | COVID‐19 Disease Map contents | User input | Tools | Output |
|---|---|---|---|---|
| Data interpretation | Online diagrams | Transcriptomics, Proteomics, Metabolomics |
The MINERVA Platform (Gawron PathVisio (Kutmon Reactome (Jassal | Visualisation of SARS‐CoV‐2 mechanisms contextualised to data |
| Diagrams in SIF format (via CasQ) | Transcriptomics | DoRothEA (Garcia‐Alonso | Contextualised evaluation of transcription factors activity under SARS‐CoV‐2 infection | |
| Diagrams in SIF format (via CasQ) |
Interactome data Proteomics | Network clustering (Messina | Identification of new SARS‐CoV‐2‐relevant interactions | |
| Mechanistic modelling | Diagrams in SIF format (via CasQ) | TranscriptomicsMetabolomics |
HiPATHIA (Salavert CARNIVAL (Liu |
Endpoint prediction Drug target effect prediction |
| Discrete modelling | Diagrams in SBML qual format (via CasQ) | Perturbation hypothesis (loss/gain of function) |
CellCollective (Helikar GINSim (Naldi BoolNet |
Perturbation outcomes: ‐ Real‐time simulation ‐ Attractor analysis |
| Stochastic & Multiscale modelling | Diagrams in SBML qual format (via CasQ) | Perturbation hypothesis (loss/gain of function) |
PhysiBoSS (Letort MaBoSS (Stoll |
Perturbation outcomes: ‐ Real‐time simulation ‐ Stochastic multiscale modelling |
Each workflow relies on the input from the C19DMap, either a direct diagram or its transformed contents, available in the GitLab repository. The workflow users may supply omics datasets to interpret them in the context of the map or test their hypotheses about how disease models will behave under specific perturbations.
Example: see Results, Case study—analysis of cell‐specific mechanisms using single‐cell expression data.
Example: see Results, Case study—RNA‐Seq‐based analysis of transcription factor activity.
Example: see Results, Case study—RNA‐Seq‐based analysis of pathway signalling.
https://colomoto.github.io/colomoto‐docker/
Figure 5Interferon type I signalling pathway diagram of the COVID‐19 Disease Map integrated with TF activity derived from transcriptomics data after SARS‐CoV‐2 infection
A zoom was applied in the area containing the most active TFs (red nodes) after infection. Node shapes: host genes (rectangles), host molecular complex (octagons), viral proteins (V shape), drugs (diamonds) and phenotypes (triangles).
Figure 6Representation of the activation levels of apoptosis pathway in nasopharyngeal swabs from SARS‐CoV‐2‐infected individuals
Activation levels were calculated using transcriptional data from GSE152075 and the Hipathia mechanistic pathway analysis algorithm. Each node represents a gene (ellipse), a human metabolite/viral protein (circle) or a function (rectangle). The pathway is composed of circuits from a receptor to an effector. Significant differential regulation of circuits in infected cells is highlighted by colour arrows (blue: inactive in infected cells). The colour of elements corresponds to the level of differential expression in SARS‐CoV‐2‐infected human nasopharyngeal swabs versus non‐infected nasopharyngeal human swabs. Blue: downregulated, red: up‐regulated and white: no statistically significant differential expression.
| Reagent/Resource | Reference or Source | Identifier or Catalog Number |
|---|---|---|
|
| ||
| CellDesigner v4.4.2 |
| |
| Newt v3.0 |
| |
| SBGN‐ED | Czauderna | |
| ySBGN |
| |
| The MINERVA Platform v15.1.4 |
| |
| Reactome |
| |
| WikiPathways |
| |
| PathVisio v3.3.0 |
| |
| INDRA | Gyori | |
| AILANI COVID‐19 |
| |
| BioKB |
| |
| OpenNLP + GNormPlus |
| |
| COVIDminer |
| |
| rWikipathways v 1.12 | 10.18129/B9.bioc.rWikiPathways | |
| OmniPathR |
| |
| The MINERVA Conversion API v15.1 |
| |
| cd2sbgml |
| |
| rnef2sbgn |
| |
| Seurat v4.0 |
| |
| DESeq2 | 10.18129/B9.bioc.DESeq2 (Love | |
| Viper v1.26.0 | 10.18129/B9.bioc.viper (Alvarez | |
| DoRothEA v1.4.1 | 10.18129/B9.bioc.dorothea (Garcia‐Alonso | |
| CaSQ v0.9.11 | Aghamiri | |
| CoV‐HiPathia | Rian | |
|
| ||
| IMEx Consortium COVID‐19 dataset | Perfetto | |
| SIGNOR 2.0 COVID‐19 dataset | Licata | |
| OmniPath | Türei | |
| INDRA EMMAA Collection, accessed: 2020.12.01 |
| |
| RNA‐Seq transcriptomic single‐cell profiles |
| |
| SARS‐CoV‐2‐infected intestinal organoids | Triana | GSE156760 |
| SARS‐CoV‐2‐infected Calu‐3 cells | Blanco‐Melo | GSE147507 |
| SARS‐CoV‐2 nasopharyngeal swabs | Lieberman | GSE152075 |